# Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

> **NCT00426855** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peter Moosmann** · enrollment: 12 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00426855
- **Lead sponsor:** Peter Moosmann
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426855, "Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00426855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*